Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial

By
Peter S. Hendricks
Sara N. Lappan
Richard C. Shelton
Adrienne C. Lahti
Karen L. Cropsey
Matthew W. Johnson
Melissa Bradley
Otto Simonsson
Lori L. Davis
Daniel H. Grossman
Cynthia E. Ortiz
May 7, 2026
0 min

Jama Network Open

Objective:

To evaluate the efficacy of psilocybin in increasing cocaine abstinence and reducing cocaine use in individuals with cocaine use disorder (CUD), hypothesizing that psilocybin would yield better outcomes than placebo.

Key Findings:

Psilocybin group showed a higher percentage of cocaine abstinent days compared to the placebo group, with a greater likelihood of complete abstinence and longer latency to first cocaine lapse.

Interpretation:

Psilocybin may be a promising therapeutic option for cocaine use disorder, demonstrating potential benefits in abstinence and reduced cocaine use, warranting further research into its long-term effects.

Limitations:

Small sample size may limit generalizability of findings, and short follow-up period may not capture long-term effects or potential biases.

Conclusion:

The study suggests that psilocybin, combined with psychotherapy, could be an effective treatment for cocaine use disorder, warranting further research with larger sample sizes.

Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial

Objective:

Key Findings:

Interpretation:

Limitations:

Conclusion:

Original Source(s)

Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial

Related Content

SAMHSA Awards $255 Million to Administer 988 Lifeline

6 takeaways from STAT’s investigation into the U.S. alcohol epidemic

Hospital-Based Management of Opioid Use Disorder in the Fentanyl Era—The Role and Limits of Expert Consensus